EUCTR2022-003205-29-SK进行中（未招募）1 期
A Phase II, randomized, placebo – controlled crossover proof-of-concept study to evaluate efficacy and safety of distal jejunal-release dextrose beads formulation (APHD-012) in subjects with a pathological Oral Glucose Tolerance Test (OGTT)
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Male and female subjects 18 – 70 years of age
- •2. Fully vaccinated against SARS-CoV-2. Full Vaccination means having received all recommended doses of a COVID-19 vaccine listed by either of WHO-Emergency Use Listing (WHO-EUL), FDA or EMA or a mix and match series composed of any heterologous combination of WHO-EUL/FDA/EMA-approved or authorized COVID-19 vaccines. Alternatively, a proven recovery from a COVID-19 infection in combination with at least one vaccination with a WHO, FDA, EMA listed vaccine qualifies as a full vaccination. The vaccination program must have been completed at least two weeks prior Informed Consent Form (ICF) signed. For the avoidance of doubt, the vaccination scheme received shall bein compliance with the current rules defined by the relevant health authorities in the US or Europe.
- •3. Body mass index 25-35 kg/m2
- •4. Subjects with an impaired glucose tolerance defined as:
- •HbA1c values =5.7% and = 6.4%
- •Impaired glucose tolerance (glucose between 140 and 199 mg/dL at the 2 hours of the Oral Glucose Tolerance Test (OGTT)) with or without impaired fasting glucose (fasting glucose between 100 and 125 mg/dL)
- •5. Stable body weight: gain or loss in body weight = 5% body weight over last 3 months
- •6. History of at least one unsuccessful effort of lifestyle modification (e.g. behavioural intervention, dieting, physical activity) to loose >5% of body weight, completed at least 3 months prior to screening. Subject may have been treated with either diet or exercise alone.
- •7. Female subjects are not pregnant or lactating, are surgically sterilized, postmenopausal (no menses for the previous 12 months). Female subjects of childbearing potential agree to undergo pregnancy tests and to use an appropriate method of contraception (i.e. surgical sterilization, intrauterine contraceptive device, oral contraceptive, diaphragm, or condom in combination with contraceptive cream, jelly, or foam or abstinence).
- •8. Male subjects agree to apply proper birth control and to not donate sperm.
- •9. Male and female subjects agree to continue to use birth control for at least 28 days after the last dose.
- •10. Willingness to undergo screening and all study procedures and examinations (i.e., physical examinations and laboratory investigations before and after the treatment periods) and to wear a continuous glucose monitoring device.
- •11. Ability to comprehend subject information and willingness to sign the informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •1. Evidence of type 2 diabetes defined by fasting plasma glucose = 126 mg/dL; 2-hour OGTT glucose = 200 mg/dL
- •2. Type I diabetes mellitus
- •3. HbA1c = 6.5%
- •4. History of proliferative retinopathy or maculopathy
- •5. Active COVID-19 infection proven by antigen positive Covid Test
- •6. Treatment with any medication for weight loss within the past 3 months before screening. Examples include: Orlistat (Xenical®, Alli®), Bupropion-naltrexone (Contrave®), Liraglutide (Saxenda®), semaglutide (Wegovy®), Phentermine-topiramate (Qsymia®).
- •7. Prior or planned weight loss surgery for obesity
- •8. Recent (within past 12 months) or planned endoscopic treatment for obesity. Examples include: Intragastric balloon (e.g. OrberaTM, ReShapeTM, ObalonTM), Natural Orifice Transluminal Endoscopic Surgery, endoscopic oral-assisted bariatric surgery procedures, including but not limited to: restorative obesity surgery, endoluminal (ROSE), StomaphyXTM, duodenojejunal bypass liner (e.g. EndobarrierTM), transoral gastroplasty (e.g., TOGA), endoscopic closure devices (e.g., Apollo OverStitchTM).
- •9. Proven history of bulimia or anorexia nervosa
- •10. Eating habits consisting of eating relevant amounts of food throughout the night (after 10 p.m.; except if working on night shifts)
- •11. Treatment with injectable anti-diabetic medications in the last 3 months (e.g., GLP-1 receptor agonists, insulin)
- •12. Treatment with dipeptidyl peptidase-4 inhibitors in the last 3 months
- •13. Confirmed medical history of liver cirrhosis
- •14. Positive test on Viral hepatitis (HbsAG, HCV)
- •15. Positive test on Human immunodeficiency virus (HIV)
- •16. Cholestatic disease
- •17. Alcohol-related liver disease including alcoholic fatty liver, alcoholic hepatitis and alcoholic cirrhosis evidenced by confirmed history of alcohol use, abnormal liver function tests defined below, and complete blood count (CBC), and/or liver biopsy.
- •18. Abnormal liver function tests:
- •Transaminases:
- •Alanine aminotransferase (ALT) = 3x upper limit of normal (ULN);
- •or Aspartate aminotransferase (AST) = 3x ULN;
- •or Alkaline phosphatase (ALP) = 2.5x ULN;
- •or total bilirubin = 2x ULN
- •19. Stage 4 hypertension (systolic blood pressure (SBP) = 180, diastolic BP (DBP) = 110)
- •20. History or presence of any uncontrolled cardiovascular, pulmonary, hepatobiliary, renal, hematological, gastrointestinal, endocrinologic, immunologic, dermatologic, neurological, psychiatric, metabolic, musculoskeletal, or malignant disease (except conditions accepted for inclusion) which the clinical investigator considers a disqualification for participation in the study.
- •21. Prior or current treatment with drugs aimed to treat abnormal glucose homeostasis including oral antidiabetics, incretin analogues and/or insulin.
- •22. History of uncontrolled illness (e.g. depression, psychosis) or behaviour that at the discretion of the investigator might confound the study results or pose additional risk in administering the study procedures.
- •23. Illicit drug abuse (marijuana, amphetamines, barbiturates, cocaine, opiates, phencyclidine and benzodiazepines)
- •24. Alcohol abuse, defined by regular consumption of alcohol within 6 months before screening defined by intake of ? 7 drinks/week for females, ? 14 drinks/week for males where 1 drink equals to 150 mL of wine or 360 mL of beer or 45 mL of hard liquor
- •25. Participation in another investigational drug/biologic or medical device study within 30 days of screening or will be enrolled in another investigational drug or medical
研究者
相似试验
进行中（未招募）
不适用
A phase IIa, placebo controlled, randomized, cross-over study to evaluate the effects of DM-83 on a meal tolerance test in subjects with type 2 diabetes mellitusMedDRA version: 9.1Level: LLTClassification code 10012614Term: Diabetes mellitus NOSDiabetesEUCTR2007-004837-41-PLDiaMedica Inc.
进行中（未招募）
不适用
A phase IIa, placebo controlled, randomized, cross-over study to evaluate the effects of DM-99 on a meal tolerance test in subjects with type 2 diabetes mellitusCukrzycaEUCTR2007-005744-24-PLDiaMedica Inc.20
进行中（未招募）
1 期
An European study to assess safety and efficacy of a new drug in patients with worsening chronic heart failurePatient with worsening chronic heart failure with left ventricular systolic dysfunctionMedDRA version: 20.0Level: LLTClassification code 10019279Term: Heart failureSystem Organ Class: 100000004849EUCTR2015-005607-92-PLQUANTUM GENOMICS75
进行中（未招募）
1 期
An European study to assess safety and efficacy of a new drug in patients with worsening chronic heart failure.Patient with worsening chronic heart failure with left ventricular systolic dysfunctionMedDRA version: 19.1Level: LLTClassification code 10019279Term: Heart failureSystem Organ Class: 100000004849EUCTR2015-005607-92-HUQuantum Genomics75
进行中（未招募）
1 期
An European study to assass safety and efficacy of a new drug in patients with worsening chronic heart failure.Patient with worsening chronic heart failure with left ventricular systolic dysfunctionMedDRA version: 20.0Level: LLTClassification code 10019279Term: Heart failureSystem Organ Class: 100000011680EUCTR2015-005607-92-CZQuantum Genomics75